BREAKING NEWS: Dexcom G7 Continuous Glucose Monitor has received FDA approval!
SDRI conducted the pivotal clinical research trials for the G7 Continuous Glucose Monitor
Sansum Diabetes Research Institute’s (SDRI) mission is to improve the lives of people impacted by diabetes through research, education, and care. We are proud to share the announcement that the FDA has approved the Dexcom G7 Continuous Glucose Monitor.
SDRI served as a clinical research site for the pivotal trial leading to the FDA approval of the Dexcom G7. Dr. Kristin Castorino, SDRI Senior Research Physician, is a co-author on a recent publication reporting the findings from the pivotal clinical trials. The Dexcom G7 CGM was evaluated for accuracy and safety in adults, and children 2 years and older.
In addition, SDRI was one of only five sites to conduct clinical research trials leading to the FDA approval for the Dexcom G7 in women living with diabetes during pregnancy.
SDRI remains focused and steadfast in our vision for improving the lives of people living with diabetes, and we celebrate with the diabetes community in this profoundly important milestone.